Related Experiment Video
Updated: Aug 3, 2026

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
Case Report: FGFR1 mutation and massive chromosome loss drive malignant transformation of low-grade gliomas
Ruze Tang1, Yanming Chen2, Dong Wan3,4
1Department of General Surgery, Children's Hospital of Soochow University, Suzhou, China.
Abstract:
The mitogen-activated protein kinase (MAPK) signaling pathway plays roles in cell proliferation, differentiation, and apoptosis, all crucial for cellular transformation. It's no surprise that MAPK alterations are prevalent in numerous tumors. Several critical genes in the MAPK signaling pathway, including BRAF, FGFR, and NF1, are mutated in brain tumors. For example, FGFR1 mutation or rearrangement has been described in pilocytic astrocytoma, diffuse astrocytoma, and dysembryoplastic neuroepithelial tumor (DNT). These MAPK-activated brain tumors are benign and seldom progress to malignancies, with the mechanisms driving this rare transformation not yet fully understood. In this study, we present two cases of high-grade glioma characterized by a single activating mutation of FGFR1 and massive chromosome loss (near-haploid genome). Similar haploidy is found in 3 additional high-grade astrocytoma by literature review, all harbor a single gene mutation in the MAPK pathway. We propose that the massive chromosome loss might serve as a significant mechanism contributing to the unusual malignant transformation of benign brain tumors activated by the MAPK pathway.
Insights
Mitogen-activated protein kinase (MAPK) pathway alterations drive benign brain tumors. Massive chromosome loss, alongside MAPK pathway gene mutations like FGFR1, may explain rare malignant transformation in these tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The mitogen-activated protein kinase (MAPK) signaling pathway is vital for cell functions and frequently altered in tumors.
- Mutations in MAPK pathway genes (e.g., BRAF, FGFR, NF1) are observed in brain tumors, often leading to benign neoplasms.
- Mechanisms underlying the rare malignant progression of MAPK-activated benign brain tumors remain unclear.

